RTP Mobile Logo
Expert Second Opinion — Investigators Discuss How They and Their Colleagues Navigate Emerging Clinical Research and Challenging Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes (Webinar Video Proceedings)
Released October 2021

Featuring perspectives from Drs Krishna Gundabolu, Richard M Stone and Eunice S Wang, moderated by Dr Harry Paul Erba. Published October 8, 2021. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows, pathologists, nurse practitioners, clinical nurse specialists, pharmacists and other healthcare providers involved in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).


    • Evaluate the importance of patient- and disease-related factors in the selection and sequencing of treatment for newly diagnosed acute myeloid leukemia (AML).
    • Summarize the outcomes from studies of venetoclax in combination with azacitidine, decitabine or low-dose cytarabine that led to FDA approval for patients with newly diagnosed AML not eligible for intensive therapy, and identify individuals appropriate for treatment.
    • Examine data from clinical trials assessing novel venetoclax-based combinations for patients with targetable mutations, and identify a potential role for those combinations in the treatment of AML.
    • Understand clinical trial results helpful in the recognition of patients with AML who might be candidates for maintenance therapy with oral azacitidine (CC-486).
    • Evaluate the long-term data with CPX-351 for newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, and identify patients eligible for treatment.
    • Develop an understanding of the mechanisms of action of, available data with and current role for available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and an IDH1 or 2 mutation.
    • Formulate a treatment plan for patients with AML with FLT3 mutations, including those who are and those who are not eligible for intensive induction therapy.
    • Appreciate the role of oral decitabine and cedazuridine for the treatment of MDS, and identify patients for whom this novel approach might be appropriate.
    • Summarize the FDA approval of luspatercept for the treatment of anemia secondary to MDS, and identify the appropriate integration into clinical practice.
    • Recall the mechanism of action of and study results with novel agents with breakthrough therapy designations for the treatment of MDS in order to quickly integrate these agents into practice once available.

    In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    PHYSICIANS: The University of Nebraska Medical Center designates this enduring activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NURSES: The University of Nebraska Medical Center designates this activity for 2 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

    CE: This CE activity consists of a video component. To receive credit, the participant should review the CE information, watch the video, complete the Post-test with a score of 80% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/UNMCPanPacificAMLMDS21/Video/CME or ResearchToPractice.com/UNMCPanPacificAMLMDS21/Video/NCPD.

    As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

    All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

    This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

    All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

    FACULTY — The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:  

    Krishna Gundabolu, MD
    Associate Professor Hematology-Oncology
    University of Nebraska Medical Center
    Omaha, Nebraska

    Advisory Committee: Blueprint Medicines, Bristol-Myers Squibb Company, Jazz Pharmaceuticals Inc, Novartis, Pfizer Inc; Contracted Research: Samus Therapeutics Inc; Ownership Interest (Stock Option): Geron.

    Richard M Stone, MD
    Professor of Medicine
    Harvard Medical School
    Chief of Staff
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, Actinium Pharmaceuticals Inc, Aprea Therapeutics, Arog Pharmaceuticals Inc, BerGenBio ASA, Boston Pharmaceuticals, Bristol-Myers Squibb Company, ElevateBio, Foghorn Therapeutics, GEMoaB, GlaxoSmithKline, Innate Pharma, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Novartis, Onconova Therapeutics Inc, Syros Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Syntrix Pharmaceuticals, Takeda Pharmaceuticals USA Inc.

    Eunice S Wang, MD
    Chief, Leukemia Service
    Professor of Oncology
    Roswell Park Comprehensive Cancer Center
    Buffalo, New York

    Advisory Committee: AbbVie Inc, Amgen Inc, Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Kura Oncology, Novartis, PharmaEssentia, Stemline Therapeutics Inc; Consulting Agreements: Mana Therapeutics, Rafael Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: AbbVie Inc, Rafael Pharmaceuticals Inc; Speakers Bureau: Astellas, DAVA Oncology, Kura Oncology, Stemline Therapeutics Inc.

    Harry Paul Erba, MD, PhD
    Director, Leukemia Program
    Instructor in the Department of Medicine
    Member of the Duke Cancer Institute
    Duke University School of Medicine
    Durham, North Carolina

    Advisory Committee and Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GlycoMimetics Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Kura Oncology, Novartis, Syros Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, Trillium Therapeutics Inc; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, ALX Oncology, Amgen Inc, Daiichi Sankyo Inc, FORMA Therapeutics, Forty Seven Inc, Gilead Sciences Inc, GlycoMimetics Inc, ImmunoGen Inc, Jazz Pharmaceuticals Inc, MacroGenics Inc, Novartis, PTC Therapeutics; Independent Review Committee: AbbVie Inc; Speakers Bureau: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis.

    UNMC AND RESEARCH TO PRACTICE CE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS —The below planning committee members have nothing to disclose:
    Neil Love, MD — RTP President and Planner, Atif Hussein, MD — RTP Reviewer, Renee Paulin, MSN, RN, CWOCN — UNMC Planner and Reviewer, Brenda Ram, CMP, CHCP — UNMC Planner, Michele Williams, DNP, AGPCNP-BC— RTP Reviewer, and Kathryn Ault Ziel, PhD—RTP Staff and Planner.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and UNMC do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Bristol-Myers Squibb Company and Takeda Pharmaceuticals USA Inc.

    Release date: October 8, 2021
    Expiration date: October 8, 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):